Events & Presentations

Presentations

Documents
Add Files June Corporate Presentation 2.1 MB
Add Files EASL 2019, Vienna, "Phase 1a Study of the Safety, Tolerability and Pharmacokinetics of ABI-H2158, a Novel Second-Generation HBV Core Inhibitor, in Healthy Volunteers" 370 KB
Add Files Assembly Bio EASL 2019 Review 1.4 MB
Add Files Interim Safety and Efficacy Results of the ABI-H0731 Phase 2a Program Exploring the Combination of ABI-H0731 with Nuc Therapy in Treatment-Naive and Treatment-Suppressed Chronic Hepatitis B Patients 581.6 KB
Add Files EASL 2019, Vienna, “Preclinical Profile of HBV Core Protein Inhibitor, ABI-H3733, a Potent Inhibitor of cccDNA Generation in HBV Infected Cells” 1 MB

Archived Events

Date	Event Details
Summary Toggle Jun 5, 2019 at 9:00 AM EDT	Jefferies 2019 Healthcare Conference Listen to webcast
Summary Toggle Apr 15, 2019 at 8:00 AM EDT	Assembly Bio EASL Data Review Click here for webcast
Summary Toggle Mar 18, 2019	Jefferies 2019 HBV Summit Listen to webcast
Summary Toggle Nov 14, 2018 at 1:20 PM GMT	Jefferies 2018 London Healthcare Conference Listen to webcast
Summary Toggle Nov 11, 2018	AASLD 2018, San Francisco, “Final Results of a Phase 1b 28 Day Study of ABI-H0731, a Novel Core Inhibitor, in Non-Cirrhotic Viremic Subjects with Chronic HBV” Supporting Materials View Presentation 1.7 MB
Summary Toggle Nov 7, 2018	5th International Workshop on HBV Cure Supporting Materials View Presentation 1.2 MB
Summary Toggle Sep 12, 2018 at 10:30 AM EDT	Morgan Stanley 16th Annual Global Healthcare Conference Listen to webcast
Summary Toggle Jun 20, 2018 at 11:30 AM EDT	Assembly Biosciences R&D Day Listen to webcast
Summary Toggle Apr 12, 2018 at 8:00 AM EDT	EASL Poster Review Webcast – ABI-H0731 Interim Phase 1b Data Listen to webcast Supporting Materials View Poster 2 MB
Summary Toggle Apr 12, 2018	EASL 2018, Paris, France, “Interim Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABI-H0731, a Novel Core Protein Allosteric Modifier (CpAM), in Healthy Volunteers and Non-Cirrhotic Viremic Subjects with Chronic Hepatitis B” Supporting Materials EASL 2018, Paris, France, “Interim Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABI-H0731, a Novel Core Protein Allosteric Modifier (CpAM), in Healthy Volunteers and Non-Cirrhotic Viremic Subjects with Chronic Hepatitis B” 2 MB
Summary Toggle Oct 22, 2017	AASLD 2017, Washington, DC, "Rapid Turnover of cccDNA in Chronic Hepatitis B Patients Who Have Failed Nucleoside Treatment Due to Emerging" Supporting Materials Rapid Turnover of cccDNA in Chronic Hepatitis B Patients Who Have Failed Nucleoside Treatment Due to Emerging Resistance 1.5 MB
Summary Toggle Oct 21, 2017	AASLD 2017, Washington, DC, "Phase 1a Safety and Pharmacokinetics of ABI-H0731, a Novel Core Protein Allosteric Modifier (CpAM) For the Treatment of Chronic HBV Infection" Supporting Materials Phase 1a Safety and Pharmacokinetics of ABI-H0731, a Novel Core Protein Allosteric Modifier (CpAM) For the Treatment of Chronic HBV Infection 1.1 MB
Summary Toggle Oct 21, 2017	AASLD 2017, Washington, DC, "Profile of Potent Second Generation CpAMs Capable of Inhibiting the Generation of HBsAg, HBeAg, pgRNA and cccDNA in HBV Infected Cells" Location Washington, DC Supporting Materials Profile of Potent Second Generation CpAMs Capable of Inhibiting the Generation of HBsAg, HBeAg, pgRNA and cccDNA in HBV Infected Cells 2.2 MB
Summary Toggle Sep 25, 2017	Discovery on Target 2017, Targeting HBV, Boston, MA "Targeting HBV Core Protein to Achieve Higher Cure Rates" Supporting Materials View Presentation 4 MB
Summary Toggle Sep 5, 2017	2017 International HBV Meeting, Washington DC, "Using a Toolbox of New and Established Mechanistic Assays to Determine How Core Protein Allosteric Modifiers (CpAMs) Inhibit HBV cccDNA Production" Supporting Materials View Presentation 3.7 MB
Summary Toggle Feb 18, 2017	APASL 2017, Shanghai, China, "Second Wave of HBV Antivirals" Supporting Materials View Presentation 4.9 MB
Summary Toggle Feb 17, 2017	APASL 2017, Shanghai, China, "Dual Mechanism of Actions of Novel HBV Core Protein Allosteric Modifiers (CpAMs): Inhibiting Viral Replication and Blocking cccDNA Formation" Supporting Materials View Presentation 3.3 MB
Summary Toggle Nov 11, 2016	The Liver Meeting® 2016, the Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, "Blockage of HBV Virus Replication and Inhibition of cccDNA Establishment by Core Protein Allosteric Modifiers" Supporting Materials AASLD_2016_Poster_FINAL_Submitted.pdf 2.8 MB
Summary Toggle Sep 21, 2016	2016 International HBV Meeting, Seoul, South Korea, "Complete Blockage of HBV Virus Replication and Inhibition of cccDNA Formation by Core Protein Allosteric Modifiers" Location Seoul, South Korea Supporting Materials View Presentation 2.4 MB
Summary Toggle Apr 15, 2016	The International Liver Congress™; 2016 Poster Presentation on Assembly's HBV Core Protein Allosteric Modifiers Supporting Materials Preclinical Characterization of Potent Core Protein Allosteric Modifiers for the Treatment of Chronic Hepatitis B poster 3.6 MB
Summary Toggle Jan 27, 2016	Gemicel® Drug Delivery System Supporting Materials View Presentation 1.5 MB

Investor Relations

Events & Presentations

Presentations

Archived Events

Jefferies 2019 Healthcare Conference

Assembly Bio EASL Data Review

Jefferies 2019 HBV Summit

Jefferies 2018 London Healthcare Conference

AASLD 2018, San Francisco, “Final Results of a Phase 1b 28 Day Study of ABI-H0731, a Novel Core Inhibitor, in Non-Cirrhotic Viremic Subjects with Chronic HBV”

Supporting Materials

5th International Workshop on HBV Cure

Supporting Materials

Morgan Stanley 16th Annual Global Healthcare Conference

Assembly Biosciences R&D Day

EASL Poster Review Webcast – ABI-H0731 Interim Phase 1b Data

Supporting Materials

EASL 2018, Paris, France, “Interim Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABI-H0731, a Novel Core Protein Allosteric Modifier (CpAM), in Healthy Volunteers and Non-Cirrhotic Viremic Subjects with Chronic Hepatitis B”

Supporting Materials

AASLD 2017, Washington, DC, "Rapid Turnover of cccDNA in Chronic Hepatitis B Patients Who Have Failed Nucleoside Treatment Due to Emerging"

Supporting Materials

AASLD 2017, Washington, DC, "Phase 1a Safety and Pharmacokinetics of ABI-H0731, a Novel Core Protein Allosteric Modifier (CpAM) For the Treatment of Chronic HBV Infection"

Supporting Materials

AASLD 2017, Washington, DC, "Profile of Potent Second Generation CpAMs Capable of Inhibiting the Generation of HBsAg, HBeAg, pgRNA and cccDNA in HBV Infected Cells"

Location

Supporting Materials

Discovery on Target 2017, Targeting HBV, Boston, MA "Targeting HBV Core Protein to Achieve Higher Cure Rates"

Supporting Materials

2017 International HBV Meeting, Washington DC, "Using a Toolbox of New and Established Mechanistic Assays to Determine How Core Protein Allosteric Modifiers (CpAMs) Inhibit HBV cccDNA Production"

Supporting Materials

APASL 2017, Shanghai, China, "Second Wave of HBV Antivirals"

Supporting Materials

APASL 2017, Shanghai, China, "Dual Mechanism of Actions of Novel HBV Core Protein Allosteric Modifiers (CpAMs): Inhibiting Viral Replication and Blocking cccDNA Formation"

Supporting Materials

The Liver Meeting® 2016, the Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, "Blockage of HBV Virus Replication and Inhibition of cccDNA Establishment by Core Protein Allosteric Modifiers"

Supporting Materials

2016 International HBV Meeting, Seoul, South Korea, "Complete Blockage of HBV Virus Replication and Inhibition of cccDNA Formation by Core Protein Allosteric Modifiers"

Location

Supporting Materials

The International Liver Congress™; 2016 Poster Presentation on Assembly's HBV Core Protein Allosteric Modifiers

Supporting Materials

Gemicel® Drug Delivery System

Supporting Materials

Search Investors